Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms

Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Amm, Joelle, Freeman, Ashley, Patel, Nihar, Aragon-Ching, Jeanny B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771418/
https://www.ncbi.nlm.nih.gov/pubmed/24069538
http://dx.doi.org/10.1155/2013/210686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771418/
https://www.ncbi.nlm.nih.gov/pubmed/24069538
http://dx.doi.org/10.1155/2013/210686

Ejemplares similares